A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by University of Pittsburgh
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Weijing Sun, MD, FACP, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT02053376
First received: January 29, 2014
Last updated: July 23, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2018
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)